Despite the advent of CFTR modulators, there remains an unmet need for new and more effective anti-inflammatory and mucoactive drugs, as CFTR correction cannot reverse established bronchiectasis, which will continue to predispose people with CF to infection and further airway inflammation, perpetuating the cycle of pulmonary damage [185]. This evidence concerns the gene CFTR and bronchiectasis.